Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Amgen stock | $206.58

Learn how to easily invest in Amgen stock.

Amgen Inc is a drug manufacturers-general business based in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Amgen employs 24,300 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Amgen

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AMGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Amgen stock price (NASDAQ: AMGN)

Use our graph to track the performance of AMGN stocks over time.

Amgen shares at a glance

Information last updated 2021-10-23.
Latest market close$206.58
52-week range$200.47 - $270.64
50-day moving average $212.60
200-day moving average $234.45
Wall St. target price$247.45
PE ratio 21.2211
Dividend yield $6.72 (3.22%)
Earnings per share (TTM) $9.86

Buy Amgen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Webull
Stocks, Options, ETFs
$0
0%
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Amgen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Amgen price performance over time

Historical closes compared with the close of $206.58 from 2021-10-27

1 week (2021-10-20) -1.47%
1 month (2021-09-27) -3.06%
3 months (2021-07-28) -15.75%
6 months (2021-04-28) -12.73%
1 year (2020-10-28) -4.53%
2 years (2019-10-28) 0.77%
3 years (2018-10-26) 11.08%
5 years (2016-10-28) 42.29%

Is Amgen under- or over-valued?

Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amgen's P/E ratio

Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Amgen shares trade at around 21x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Amgen's PEG ratio

Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5601. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Amgen's EBITDA

Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.4 billion.

The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure a its profitability.

Amgen financials

Revenue TTM $25.5 billion
Operating margin TTM 35.76%
Gross profit TTM $19.3 billion
Return on assets TTM 9.13%
Return on equity TTM 60.79%
Profit margin 22.55%
Book value $14.48
Market capitalisation $118.8 billion

TTM: trailing 12 months

Shorting Amgen shares

There are currently 11.1 million Amgen shares held short by investors – that's known as Amgen's "short interest". This figure is 4.7% down from 11.6 million last month.

There are a few different ways that this level of interest in shorting Amgen shares can be evaluated.

Amgen's "short interest ratio" (SIR)

Amgen's "short interest ratio" (SIR) is the quantity of Amgen shares currently shorted divided by the average quantity of Amgen shares traded daily (recently around 2.6 million). Amgen's SIR currently stands at 4.34. In other words for every 100,000 Amgen shares traded daily on the market, roughly 4340 shares are currently held short.

However Amgen's short interest can also be evaluated against the total number of Amgen shares, or, against the total number of tradable Amgen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amgen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Amgen shares in existence, roughly 20 shares are currently held short) or 0.0196% of the tradable shares (for every 100,000 tradable Amgen shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amgen.

Find out more about how you can short Amgen stock.

Amgen's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Amgen's total ESG risk score

Total ESG risk: 20.95

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Amgen's environmental score

Environmental score: 1.53/100

Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Amgen's social score

Social score: 15.13/100

Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Amgen's governance score

Governance score: 5.8/100

Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Amgen's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Amgen Inc was last rated for ESG on: 2019-01-01.

Total ESG score 20.95
Total ESG percentile 23.7
Environmental score 1.53
Environmental score percentile 3
Social score 15.13
Social score percentile 3
Governance score 5.8
Governance score percentile 3
Level of controversy 2

Amgen share dividends

43%

Dividend payout ratio: 43.3% of net profits

Recently Amgen has paid out, on average, around 43.3% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.36% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 3.36% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $6.72 per share.

While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.

Amgen's most recent dividend payout was on 7 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 15 August 2021 (the "ex-dividend date").

Have Amgen's shares ever split?

Amgen's shares were split on a 2:1 basis on 21 November 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.

Amgen share price volatility

Over the last 12 months, Amgen's shares have ranged in value from as little as $200.47 up to $270.6403. A popular way to gauge a stock's volatility is its "beta".

AMGN.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.6825. This would suggest that Amgen's shares are less volatile than average (for this exchange).

Amgen overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

Frequently asked questions

What percentage of Amgen is owned by insiders or institutions?
Currently 0.199% of Amgen shares are held by insiders and 77.879% by institutions.
How many people work for Amgen?
Latest data suggests 24,300 work at Amgen.
When does the fiscal year end for Amgen?
Amgen's fiscal year ends in December.
Where is Amgen based?
Amgen's address is: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
What is Amgen's ISIN number?
Amgen's international securities identification number is: US0311621009
What is Amgen's CUSIP number?
Amgen's Committee on Uniform Securities Identification Procedures number is: 031162100

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site